Currently, multitarget tyrosine kinase inhibitors (TKIs) and mechanistic target of rapamycin kinase (mTOR) inhibitors have become major breakthroughs in the treatment of ccRCC. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.